U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

Clin Infect Dis. 1999 Jan;28(1):49-51. doi: 10.1086/515086.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Antiprotozoal Agents / administration & dosage
  • Antiprotozoal Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Approval*
  • Drug Carriers
  • Humans
  • Leishmaniasis, Visceral / drug therapy*
  • Liposomes
  • United States
  • United States Food and Drug Administration

Substances

  • Antiprotozoal Agents
  • Drug Carriers
  • Liposomes
  • liposomal amphotericin B
  • Amphotericin B